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Abstract: There are numerous defense proteins present in the saliva. Although some of 
these molecules are present in rather low concentrations, their effects are additive and/or 
synergistic, resulting in an efficient molecular defense network of the oral cavity. 
Moreover, local concentrations of these proteins near the mucosal surfaces (mucosal 
transudate), periodontal sulcus (gingival crevicular fluid) and oral wounds and ulcers 
(transudate) may be much greater, and in many cases reinforced by immune and/or 
inflammatory reactions of the oral mucosa. Some defense proteins, like salivary 
immunoglobulins and salivary chaperokine HSP70/HSPAs (70 kDa heat shock proteins), 
are involved in both innate and acquired immunity. Cationic peptides and other defense 
proteins like lysozyme, bactericidal/permeability increasing protein (BPI), BPI-like 
proteins, PLUNC (palate lung and nasal epithelial clone) proteins, salivary amylase, 
cystatins, prolin-rich proteins, mucins, peroxidases, statherin and others are primarily 
responsible for innate immunity. In this paper, this complex system and function of the 
salivary defense proteins will be reviewed. 
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1.1. Saliva and the Oral Cavity  
Saliva is a body fluid, secreted by three pairs of major salivary glands (parotid, submandibular and 
sublingual) and by many of minor salivary glands [1,2]. Primary saliva is secreted in secretory 
endpieces (acini) of salivary glands. Primary saliva is modified by serum exudates via tight junctions 
between several glandular cells (ultrafiltration) and via transcellular diffusion through these cells. 
Primary saliva is also modified in the intercalated, striated and excretory (collecting) ducts leading 
from the acini to the mouth. Entering the mouth, ductal saliva of several salivary glands are blended, 
and supplemented with many constituents that originate from intact or destroyed mucosal cells, 
immune cells, and oral microorganism [1,2]. Blood constituents also enter the oral cavity via gingival 
crevicular fluid, via the mucosa as mucosal transudate, and via intraoral bleeding [1,2]. Consequently, 
a complex mixture of a high variety of molecules is the result in the oral cavity, frequently called 
“mixed saliva” and/or “whole saliva” in the scientific literature.  
Whole saliva is a major determinant of the environment on all the oral surfaces. On tooth surfaces 
saliva plays an important role in acquired pellicle formation, which is a thin (ca. 0.5–1 μm) layer of 
several salivary proteins with calcium hydroxide binding properties [1,2]. Acquired pellicle plays a 
major role in crystal growth homeostasis of the teeth, and in physico-chemical defense of tooth 
surfaces. Acquired pellicle plays a major role in bacterial adhesion (and colonization) on tooth surfaces 
which may disadvantageously lead to caries formation and periodontal inflammation (especially in the 
absence of proper oral hygiene) [1,2]. Acquired pellicle, however, may also be considered as an 
important tool for advantageous surface exclusion of transient pathogen microbes entering the mouth 
(i.e., infectious viruses such as influenzas). Besides defense of tooth surfaces, saliva plays an important 
role in physico-chemical as well as immune defense of the oral (and upper gastro intestinal) mucosal 
surfaces (via both direct antimicrobial action, as well as agglutination or surface exclusion of 
microbes). Saliva also plays important role in the healing of several mucosal lesions, wounds and 
ulcers as well [1,2].  
1.2. The Innate and Acquired Oral Immunity 
There are numerous defense proteins present in the saliva. Some of these defense proteins, like 
salivary immunoglobulins, and salivary chaperokine HSP70/HSPA, are involved in both innate and 
acquired immune activation [2–4]. Salivary cationic peptides and other salivary defense proteins, like 
lysozyme, BPI, BPI-like and PLUNC proteins, salivary amylase, cystatins, prolin-rich proteins, 
mucins, peroxidases, statherin (and others), are primarily responsible for innate immunity [1,2]; 
notwithstanding that, many of them also exert immune activator and/or immune modulator properties. 
Importantly, many of these molecules are present in rather low concentrations in whole saliva; 
however, it should be considered that their effects are cumulative and/or synergistic, resulting in an 
efficient molecular defense network of the oral cavity [1,2,5]. It should be also considered that local 
concentrations of these proteins near the mucosal surfaces (mucosal transudate), periodontal sulcus 
(gingival crevicular fluid) and oral wounds and ulcers (transudate) may be much greater, and in many 
cases reinforced by immune and/or inflammatory reactions of the oral mucosa [3,4]. Binding of Int. J. Mol. Sci. 2012, 13  4297 
 
 
salivary defense proteins onto the tooth and/or mucosal surfaces may also lead to an enrichment [6–8] 
of these proteins on tooth [7] and mucosal surfaces [8]. It is also likely that their basic properties are 
not altered via such binding [7–9]; moreover, surface binding may improve their resistance against 
proteolytic degradation via microbial proteases [10]. Besides the above, there may be an enrichment of 
defense proteins through participation in the formation of salivary micelles as well [11,12]. 
Concentration of salivary defense proteins may also be rather high near those cells, producing several 
defense proteins (i.e., mucosal epithelial cells and neutrophil granulocytes entering the oral cavity).  
1.3. Expected Network Action of the Salivary Defense System 
As it was pointed out above, most (if not all) salivary defense proteins may enrich concentrations to 
“efficient” levels in certain locations in the oral cavity [1–4], notwithstanding that many of them are 
found in the whole saliva in less-than-efficient concentrations [13]. In these locations, a “single hit” 
type of action (one type of agent affects the target [14]) of salivary defense proteins may occur. 
However, salivary proteins (including cationic peptides) may also provide antimicrobial defense, even 
if they are present in concentrations that are lower than efficient. In this case, a network type,   
“multi-hit” approach may be expected. In this case, several kinds of salivary defense proteins affect the 
targeted microbe at the same time. Although in this case a certain salivary protein may induce a 
“partial knockout” [14] of the targeted microbe only, their network type “acting together” at the same 
time may lead to efficient elimination of the target. 
We may expect five primary defense networks of salivary proteins in whole saliva. The first 
network may be responsible for microbial agglutination and/or surface exclusion. This network may 
include those salivary proteins and peptides which bind bacteria (microbes) and also bind to either oral 
surfaces [6–9] or each other [11,12] or both. The second network may be expected to be responsible 
for lysis of microbial membranes. This network primarily targets bacteria, and are likely to include 
salivary cationic peptides and lysozyme (the latter is likely to improve the efficiency of cationic 
peptides, as described later). The third and fourth networks may be responsible for antifungal [15,16] 
and antiviral [17] properties of the saliva respectively. These networks may include numerous salivary 
proteins exerting various antifungal [15,16] or antiviral [17] properties respectively. Finally, a fifth, 
immune regulatory network of salivary proteins may also be expected. This network is likely to 
include all those salivary proteins which exert immune activator/modulator properties. This network 
may be important for the fine-regulation of the local action of the mucosal immune system. 
1.4. Multifunction Character of Salivary Defense Proteins  
In the following paragraphs, the most important molecular participants (i.e., defense proteins and 
peptides) responsible for the maintenance of the complex oral innate and acquired immune defense 
system will be introduced in detail. During their introduction it will be pointed out that most of these 
proteins (and peptides) are multifunctional [1,2,5], and that their action may even overlap in several 
cases [1,2]. This multifunctional character of salivary defense proteins also refers to their ability to act 
together in a “multi hit” network type approach (as expected above).  
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2. Salivary Antibodies 
2.1. Major Classes of Salivary Antibodies 
Salivary antibodies act in the first line of defense by performing immune exclusion of antigens in 
the saliva, in the mucus layer on the epithelial surfaces [18] and in the acquired pellicle on the tooth 
surfaces. They are constitutively excreted into the saliva and the oral cavity. There are two major 
antibody classes in human saliva, namely secretory IgA (sIgA) and IgG [1,2,18]. Secretory IgA is 
primarily of salivary gland and (in fewer amounts) of mucosal cell origin [18–20] and primarily 
dimeric (although in some cases may be polymeric) [18]. Salivary IgG is monomeric and either serum 
derived or produced by local plasma cells [18]. There is also a small fraction (15% of total salivary 
IgA) of monomeric (non-secretory) IgA in the saliva which is also either serum-derived or produced 
by local plasma cells, similarly to IgG [18]. Although the majority of salivary antibodies belong to IgA 
(90–98%) and IgG (1–10%) [1,2] classes, there are some very small fractions of IgM, IgD and IgE 
antibodies in the saliva as well [2,18]. 
Serum derived IgG and monomeric (non-secretory) IgA mainly enter the oral cavity via the gingival 
crevicular fluid [1,2,18], but also via mucosal transudate and via ultrafiltration through the salivary 
gland acini [1,2,18]. Similarly, local plasma cell produced monomeric (non-secretory) IgA and IgG 
may also enter the oral cavity via mucosal transudate and via acinar ultrafiltration [1,2,18]. 
Importantly, the numbers of antibodies transported through premised routes may strongly be 
influenced by certain oral conditions, such as gingival and mucosal inflammations, as well as by the 
integrity of the mucosal and acinar epithelial barrier [1,2,18].  
2.2. Production of Salivary Secretory Antibodies 
The initial stimulation of secretory immunoglobulin expressing B-cells (capable of differentiating 
into dimeric/polymeric antibody producing plasma cells) takes place in mucosa associated lymphoid 
tissues (MALT), such as gut-associated lymphoid tissues (GALT) and nasopharynx-associated 
lymphoid tissues (NALT) [18,21]. Notwithstanding that activated B-cells can migrate from GALT to 
salivary glands and are able to induce significant salivary secretory immunoglobulin response [18,21], 
in general, intestinal immune induction seems to be not so well reflected in the salivary   
secretory immunoglobulin system [18]. Thus, NALT tissues (i.e., adenoids and palatine tonsils of the 
Waldeyer’s ring), orchestrating regional immune functions against both airborne and alimentary 
antigens, are likely to be the primary inductive sites for B-cells (capable of differentiating into 
dimeric/polymeric antibody producing plasma cells) destined to the salivary glands [18] and   
oral mucosa.  
Salivary secretory immunoglobulins, namely secretory IgA (sIgA), and the very small amount of 
secretory IgM (sIgM), are produced by specific plasma cells residing primarily in the salivary 
glandular stroma and, in smaller numbers, also in the oral mucosa [19,20]. These plasma cells release 
mainly dimeric (but also some polymeric) IgA molecules and a few pentameric IgM molecules, all of 
which are stabilized by an incorporated 15 kDa J chain [18]. Both dimeric/polymeric IgA and 
pentameric IgM molecules are internalized from the interstitium and exported to the saliva by acinar 
cells (serous-type) and ductal cells (intercalated type) of minor and major salivary glands via a Int. J. Mol. Sci. 2012, 13  4299 
 
 
common salivary gland epithelial transport mechanism utilizing the polymeric immunoglobulin 
receptor (pIgR) and its major chain, the secretory component (SC) [18]. Importantly, secretory 
immunoglobulin A (and may be also sIgM) is constitutively excreted into the saliva even in the 
absence of stimulation [22]. A similar transport mechanism from the mucosal interstitium to the oral 
mucosal surface is also very likely in the case of oral mucosal epithelial cells [19,20]. However, the 
amount of oral mucosal epithelial transport seems to be much lower, compared to that of salivary 
glands [19]. 
2.3. The Secretory Component of pIgR 
The secretory component (SC) of the polymeric immunoglobulin receptor (pIgR) exhibits strong 
affinity for the J chain of dimeric and polymeric IgA and pentameric IgM [18]. It appears to have 
similar affinity for both subtypes of polymeric IgA (IgA1 and IgA2; the latter is more resistant to 
certain bacterial proteases [23]); therefore both are equally well exported by the pIgR (containing SC) 
into the secretion [18]. The polymeric immunoglobulin receptor (pIgR) is a carbohydrate-rich 100 kDa 
glycoprotein constitutively expressed on the basolateral surface of glandular epithelial cells [18] and 
mucosal epithelial cells [20]. At the basolateral epithelial surface, the J chain of dimeric/polymeric IgA 
and pentameric IgM binds to SC (of pIgR), leading to a selective “lock and key” initialization of the 
molecular transport [18]. This molecular transport starts with the internalization of SC bound (pIgR 
bound) dimeric/polymeric antibodies at the basolateral cell surface and finished by the exocytosis of 
SC binding antibodies at the apical cell surface into the glandular lumen (or into the oral cavity in the 
case of mucosal epithelial transport). The process of exocytosis is coupled with the cleavage of the 
secretory component (SC) from the pIgR. Thereafter, the 80 kDa SC (former part of the 100 kDa pIgR) 
remains incorporated into the sIgA and sIgM antibodies permanently, endowing the secretory 
immunoglobulins with resistance against proteolytic degradation [18].  
The expression of SC (pIgR) can be enhanced by cytokines [24] and excess, unoccupied pIgR (SC) 
is released from glandular cells (in the same manner by proteolytic cleavage as above), resulting in the 
presence of free secretory components (also of 80 kDa) in the saliva [18]. A similar release of free SC 
from those mucosal epithelial cells that discharge secretory immunoglobulins may also be expected. 
Importantly, free SCs exert several innate defense functions in the mouth, such as inhibition of 
epithelial adhesion of certain bacteria via (nonspecific scavenger type [25]) binding of bacterial 
fimbrial adhesins [26], as well as neutralization of certain bacterial toxins [27]. Immunoglobulin 
bounded SC exerts mucophilic properties and significantly contributes to the proper anchorage of sIgA 
to the mucus layer lining the mucosal surface [25,28]). As a non-specific microbial scavenger [25], 
immunoglobulin bounded SC may also play a role in the phenomenon that secretory antibodies show 
much better agglutinating properties than monomeric antibodies. 
2.4. Antigen Binding, Agglutination and Surface Exclusion 
The primary function of salivary (secretory and other) immunoglobulins is to inactivate parasites: 
bacteria, fungi and viruses (as well as certain microbial toxins) via binding and/or agglutination of 
such particles [18,29–31]. Such binding and/or agglutination may prevent mucosal adhesion of 
microbes and their toxins [30,31] and can lead to clearance toward the stomach, resulting in a Int. J. Mol. Sci. 2012, 13  4300 
 
 
consequent acidic digestion [30]. Surface immune exclusion (fixation to surfaces and immobilization 
until elimination) of the pathogens within the oral cavity via anchorage of secretory   
immunoglobulin-binding antigens to the superficial mucous layer lining the mucosal surface is another 
important mechanism to prevent invasion of the underlying tissues [25,32]. Since immunoglobulins are 
usually participants of the acquired pellicle of the teeth and promote microbial adhesion onto tooth 
surfaces, premised processes of immune exclusion are also very likely to occur on the surfaces of 
teeth. Surface immune exclusion seems to be an efficient and advantageous defense mechanism 
against those pathogenic microbes which are not dangerous to the oral tissues locally (i.e., influenza 
viruses, bacteria responsible for enteritis or pneumonia etc.) [25,32]. However, it should also be 
considered that surface immune exclusion may also lead to the oral appearance and existence of 
immobilized microbes being strongly pathogenic locally (i.e., cariogenic or periodontopathogenic 
bacteria etc.). Surface immune exclusion-related immobilization of microbes on tooth surfaces may 
also promote disadvantageous microbial biofilm formation on teeth (i.e., dental plaque) in the absence 
of proper oral hygiene [1,2]. 
2.5. Phagocytosis, Antigen Presentation, Degranulation and Cytokine Production 
Antigen binding and agglutination may also lead to phagocytosis (followed by antigen presentation 
and lysis) [18,30], as well as degranulation and cytokine production in the presence of   
immune-competent cells [33]. The oral mucosal surface is extensively populated by antigen presenting 
cells (i.e., Langerhans and dendritic cells) and there is also a considerable flux of neutrophil 
granulocytes through the gingival sulcus into the saliva even in the healthy. Since both dendritic cells 
and neutrophil granulocytes have immune activating IgA receptors [33] on their surfaces, premised 
immune-cell coupled defense functions of salivary IgA (and maybe also other immunoglobulins) are 
likely to be active to maintain immune surveillance, also in healthy subjects. In the case of oral 
mucosal lesions and wounds, other immune-competent cells are certainly also available for a much 
more active immune defense reaction. 
2.6. Antibody Catalyzed Ozone Formation 
In the presence of reactive oxygen intermediate (ROI)-producing neutrophil granulocytes [34], 
salivary antibodies can catalyze ozone formation leading to efficient microbial killing [35–37]. During 
this process, antibodies kill microbes by catalytically converting a less toxic ROI (namely singlet 
dioxygen supplied by the neutrophils) to a mixture of hydrogen peroxide and ozone [38]. This strongly 
improves the efficiency of killing, because, on the one hand, ozone is a very powerful oxidant, and on 
the other, no microbial enzymes are known to catabolize ozone [38]. Importantly, all immunoglobulins, 
regardless of their source or antigenic specificity [35,36], are able to induce and catalyze such ozone 
formation; thus, antibodies bridge innate and adaptive immunity in this respect [38]. Interestingly, it is 
not only intact antibodies that are able to catalyze the reaction, but also their fragments [39], as well as 
certain single amino acids (namely tryptophan, methionine, cysteine and histidine) [40]. 
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2.7. Other Functions of Dimeric/Polymeric Antibodies 
Besides the above, there are some other dimeric/polymeric immunoglobulin-related mechanisms 
which also contribute to mucosal immune defense against antigens (primarily viruses and microbial  
toxins) [25,32]. For example, polymeric immunoglobulin receptor (pIgR) is able to bind and 
internalize antigen loaded dimeric/polymeric immunoglobulins on the basolateral epithelial cell 
surfaces and exocytose the antigen-immunoglobulin complex in the apical side of the cell into the 
glandular lumen (or into the oral cavity in case of mucosal epithelial transport) [25,32]. It may also 
occur that the pathogen is neutralized in the epithelial cell during this antibody coupled pIgR driven 
transport [25,32]. Similarly, dimeric/polymeric immunoglobulins being transported through the 
epithelial cells (during pIgR mediated transcytosis as above) can bind intracellular antigens (i.e., 
invading viruses or bacterial lipopolysaccharide /LPS/ toxins) and thereby perform intracellular 
antigen neutralization and clearance which inhibits epithelial cell damage and prevents the appearance 
of inflammation [32,41]. Premised pathways suggest important clearing mechanisms targeting (and 
eliminating) those antigens already invading the epithelial cells and/or the underlying glandular and 
mucosal tissues (i.e., glandular stroma and lamina propria mucosae) [25,32].  
Although salivary IgA (including both secretory and monomeric forms) does not activate a 
complement system by direct means, salivary IgG type antibodies, however, are complement   
activating [32]. Salivary IgG-induced complement activation may occur in healthy subjects near the 
gingival sulcus, because the composition of the gingival crevicular fluid is very similar to serum 
transudate (even in healthy subjects) containing also the complement system. In the case of oral 
mucosal lesions and wounds, salivary IgG-induced complement activation may also occur in the 
injured regions of the oral mucosa.  
3. Salivary Chaperokine HSP70/HSPAs 
3.1. The HSP70/HSPA Protein Family  
The HSP70/HSPA type proteins are 70 kDa major molecular chaperones and cytokine   
chaperokines [42] of most cells and tissues, extracellular and interstitial fluids, blood, synovial fluids, 
and also secreted body fluids, like saliva [43–45]. Extracellular HSP70/HSPAs reveal cytoprotective 
properties through cell surface association, which may be followed by internalization. Extracellular 
HSP70/HSPAs are also involved in a number of physiological and pathological events, including 
modulation of cytokine release, immunity, and the modulation of neuronal function [42,45].   
In addition, HSP70/HSPAs are able to enter the bloodstream, and possess the ability to act at distant 
sites of the body as an ancestral danger signal triggered by cell injury, immune-inflammatory 
reactions, and physical or behavioral [44] stress of the organism.  
As mentioned above, the presence of HSP70/HSPAs in human saliva was also demonstrated 
[43,44]. It is very likely that both constitutively expressed and stress inducible forms of HSP70/HSPA 
proteins are also present in human saliva (see also below) [43,44,46]. The presence of HSP70/HSPA 
proteins in the oral environment refers to the extracellular functions of Hsp70/HSPA proteins that 
should also be considered in relation with oral defense mechanisms. 
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3.2. Origin of Salivary HSP70/HSPAs 
Salivary glands are among the main sources of HSP70/HSPAs in the saliva [3,43,44]. Although it 
has not yet been investigated in detail, it is very likely that HSP70/HSPAs of glandular origin are a 
mixture of both constitutively expressed and stress inducible forms of HSP70/HSPA [3,43,44].   
The level of salivary HSP70/HSPAs shows large differences between subjects in both mixed (whole) 
saliva and cannulated parotid duct saliva [46]. Within a subject, there are also differences, maybe 
because of the prompt inducibility of salivary HSP70/HSPAs via several stimuli [43,44]. It is very 
likely that HSP70/HSPAs are not secreted due to the classical secretory exocytotic process of the 
acinar cells [43,44]. The transport of HSP70/HSPAs may involve passive transport via the salivary 
glands (and their ducts) from blood serum [3,43,44], and/or the possibility of small capacity active 
transport from the striated duct cells of human salivary glands [3,43,44]. An alternative transport of 
HSP70/HSPAs may also occur either through lipid rafts or through exosomes [3,43,44]. 
Besides salivary glands, there are also other important sources of salivary HSP70/HSPAs, such as 
mucosal cells [3,43,44], gingival crevicular fluid [3,43,44], the oral mucosal transudate [2,4], and 
intraoral bleeding (i.e., bleeding periodontal pockets, wounds, ulcers) [2,4]. There are also identified 
bacterial, fungal or parasitic homologues of HSP70/HSPA proteins in the oral cavity. Their sources are 
oral bacteria and other oral microbes [2,4,46].  
3.3. Binding of Bacteria, Agglutination and Surface Exclusion 
Salivary HSP70/HSPAs may entrap and agglutinate bacteria [46]. Recent data has indicated that 
salivary HSP70/HSPAs bind both gram-positive (Streptococcus mutans and mitis) and gram-negative 
(Escherichia coli) bacteria [46–48]. Since HSP70/HSPAs are known to be able to form dimers and 
oligomers, the agglutinating function of salivary HSP70/HSPAs could be efficient. It is also possible 
that HSP70/HSPAs occur in micelles and/or in smaller homo/heterotypic complexes, which are also 
known to enhance agglutination in saliva [11]. Importantly, salivary HSP70/HSPAs also bind 
hydroxyapatite—the major inorganic component of tooth surfaces [46]. Therefore, it is likely that 
salivary HSP70/HSPAs may play a role in the acquired pellicle formation followed by bacterial 
adhesion on tooth surfaces. The capability to take part in the acquired pellicle formation and to bind 
bacteria refers to the facility of salivary HSP70/HSPAs bacteria to colonize tooth surfaces, which may 
lead to dental caries and periodontal inflammation. On the other hand, binding of both tooth surfaces 
and bacteria may also lead to surface exclusion of those bacteria, which are not harmful locally but 
may be pathogenic for the whole organism. 
3.4. Immunological Defense Mechanisms 
Three major facets of immune activation have been described for salivary HSP70/HSPAs [3,43,44]. 
The first facet of immune activation involves released extracellular HSP70/HSPA as an ancestral 
danger signal of cellular stress, death or lysis. Importantly, both uncomplexed (“free”) and membrane 
bound (lipid rafts, exosomes) HSP70/HSPAs were shown to express such danger signal properties [49]. 
The immune activation here is very similar to that of bacterial lipopolysaccharides (LPS) and the 
effects of LPS and extracellular HSP70/HSPAs seem to be additive [49]. HSP70/HSPAs as danger Int. J. Mol. Sci. 2012, 13  4303 
 
 
signals may induce the release of proinflammatory cytokines from several immune cells (i.e., 
monocytes, dendritic cells, macrophages, T lymphocytes), release of NO from macrophages, activation 
of NK cells and activation of complement via an antibody-independent alternative pathway [49–51]. 
HSP70/HSPA proteins also act as cytokines and chemikones in the presence of immune cells.   
These facets of immune function could be effective in the case of oral mucosal lesions (i.e., oral 
wounds and ulcers), because inflammatory serum exudate containing a high amount of complement 
system, immunoglobulins, immune/inflammatory mediators as well as PMN leukocytes, and 
monocytes/macrophages are usually also present on the surface of oral lesions [3,4,46].  
The second facet of immune system activation involves complexes of extracellular HSP70/HSPA 
proteins and other peptides. Because of the chaperoning ability, uncomplexed HSP70/HSPA binds 
other peptides, and as complex induced receptor-mediated uptake into antigen-presenting cells   
(i.e., macrophages, Langerhans and dendritic cells) to cross-present this complex as an antigen 
(coupled with MHC-I or MHC-II molecules) to cytotoxic T cells and NK cells [52]. This mechanism is 
important in the defense against bacteria (and other microbes), and also as an initiator of immune 
defense against tumor cells and virus-infected cells. Since oral mucosa (especially non-keratinized 
parts) is extensively populated by antigen-presenting Langerhans and dendritic cells [53] (from which 
Langerhans cells are properly oriented to “sample” the oral fluids with their dendrites toward the 
surface [53,54]), these facets of immune function can be efficient in the mouth.  
The third facet is based on the recent finding that HSP70/HSPA proteins exert an opsonizing effect 
on bacteria, which activate the killing activity of polymorphonuclear neutrophil granulocytes [47,48]. 
Although there is a considerable flux of neutrophils through the gingival sulcus into the saliva, even in 
the healthy, this function may be especially effective under inflammatory conditions (i.e., gingival 
inflammations) and in the case of oral lesions (i.e., ulcers, wound healing) [46].  
3.5. Further Defense Functions of Salivary HSP70/HSPAs 
Besides the above, there may be other defense functions of salivary HSP70/HSPAs, based on the 
known cytoprotective effects of extracellular HSP70/HSPA proteins [55,56]. The cytoprotective 
effects seem to be based on three different mechanisms. Aspecific binding of Hsp70/HSPA on mucosal 
cell surfaces [55] may lead to surface defense against toxins [55]. A more specific adhesin-type 
binding to sulfoglycolipid structures of mucosal cells [57] may prevent bacterial colonization of 
mucosal surfaces through occupying mucosal binding sites of HSP70/HSPA related bacterial adhesins. 
Surface receptor binding of HSP70/HSPAs may also occur, which is mostly followed by 
internalization [45,56]. To date, a decrease in cell apoptotic and necrotic liability [58] and the release 
of several cytokines [59,60] are the most important proven mechanisms of HSP70/HSPA   
receptor-induced cytoprotection.  
Further, another defense mechanism has also been hypothesized [46], based on the finding that 
fungicidal activity of salivary Histatin-5 (see also below) is initiated by binding to surface 
HSP70/HSPA homologues of Candida albicans (Ssa1p, Ssa2p), followed by internalization and later 
cell death [61,62]. This finding may indicate that Histatin-5 may bind human salivary HSP70/HSPA 
too. Although there is no evidence that such a salivary HSP70/HSPA-Histatin-5 complex would also Int. J. Mol. Sci. 2012, 13  4304 
 
 
be able to enter and destroy C albicans, this possibility should still be considered rather than simply 
excluded [46].  
4. Cationic Peptides  
4.1. Defensins  
Defensins are “prototype” of cationic peptides. They are characterized by a “hairpin-like” globular 
structure stabilized by three intramolecular disulfide bridges linking six cysteine amino acids [54]. 
Based on the pattern of cysteine-pairing, two main subfamilies are distinguished, namely the   
α-defensins and the β-defensins [54,63]. Salivary α-defensins (HNP1, HNP2, HNP3, HNP4) are 
produced by neutrophil granulocytes [13,63], whereas salivary β-defensins (hBD1, hBD2, hBD3, 
hBD4) are produced by mucosal cells [13,63,64]. Besides whole saliva, both α- and β-defensins are 
also present in the gingival crevicular fluid [13]. Both α- and β-defensins show broad antibacterial 
activity, based on their cationic peptide character [13,63]. Their first interaction with bacteria is 
typically mediated by their positive net charge. In contrast to eukaryotic cells carrying no or little net 
charge on the outer leaflet of their cell membrane, outer leaflets of bacterial cell membranes are 
typically negatively charged [63]. Cationic peptide defensins adsorb via electrostatic forces onto the 
negatively-charged bacterial cell membrane leading to their subsequent aggregation and integration 
into the lipid bilayer [63,65]. Integration of defensins into the bacterial membranes results in the 
formation of ion channels, transmembrane pores, membrane leakages and membrane rupture [65], 
leading to the destruction of the bacteria. How cationic peptides (including defensins) manage to get 
across polysaccharide bacterial capsules (if any) and peptidoglycan layers of bacterial membranes is 
far not fully understood yet, however, digestion of peptidoglycans via salivary lysozyme is likely to be 
an important assistance to get across the peptidoglycan layers. Importantly, antibacterial activity of 
most defensins (but not of hBD3) can be neutralized by higher salt concentrations (i.e., 100 mM 
monovalent or 2 mM divalent cations) [66], which may also be present transiently in stimulated   
(i.e., chew and/or taste) saliva [2]. Besides their broad antibacterial activity, defensins also exert 
antifungal and antiviral properties [17,63]. An antifungal effect of β-defensins is likely to occur via 
binding of fungal HSP70-type surface proteins (in particular: Ssa1p of Candida albicans [15]) may be 
followed by an internalization process similar to that of histatin-5-dependent antifungal activities (see 
below). Defensins also exert various immune activator and modulatory activities, including induction 
of certain cytokines and chemoattractivity for immature dendritic and memory T-cells [63]. 
4.2. Histatins 
Histatins are small histidine-rich cationic peptides ranging in size from 7 to 38 amino acids. 
Histatins are secreted by the parotid gland as well as the sublingual and submandibular glands [13,67]. 
There are about a dozen histatins (HRPs), of which the most important are: histatin-1, histatin-2, 
histatin-3 and histatin-5 (this last one is a proteolytic cleavage derivative of histatin-3 [13]) accounting 
for 85–90% of this family. Histatins exert broad-spectrum antibacterial as well as antifungal   
properties [63,68]. Histatins also show antiviral properties [17]. As cationic peptides, histatins adsorb 
via electrostatic forces onto the negatively charged bacterial cell membranes leading to subsequent Int. J. Mol. Sci. 2012, 13  4305 
 
 
histatin aggregation followed by their integration into the lipid bilayer [63,65]. Their integration into 
the bacterial membrane is likely to lead to the formation of ion channels, transmembrane pores, 
membrane leakages and membrane rupture [65], causing destruction of bacteria. Histatins also bind 
and complex Cu
2+ and Ni
2+ ions [63,69], leading to the elimination of metal ions and the consequent 
inhibition of enzymes, their cofactors and microbial growth [63,69,70]. Histatins (especially histatin-5) 
also exert efficient activities against fungi (in particular: against the yeast Candida albicans) [68]. This 
antifungal activity is initiated by binding histatin-5 to certain HSP70-type surface proteins (Ssa1p, 
Ssa2p) of Candida albicans, followed by internalization of histatin-5 and consequent cell death [61,62]. 
HRP5 was also shown to inhibit a trypsin-like protease of Bacteroides gingivalis [71]. Histatins 
(especially histatin-1) are also incorporated into the acquired pellicle on tooth surfaces [9], and 
therefore may play a role in bacterial colonization (and/or surface exclusion of bacteria) on tooth 
surfaces. On the other hand, histatin-1 was also shown to competitively inhibit the absorption of high 
molecular weight glycoproteins (HMWGPs) to tooth surfaces, and therefore may inhibit adhesion of 
HMWGP-binding cariogenic bacteria (i.e.,  S. mutans [72]) onto tooth surfaces [72]. Histatins 
(especially histatin-2, but also histatin-1 and histatin-3) were also identified as highly important wound 
closure stimulating factors of human saliva [68]. HRPs also inhibit (precipitate) tannins, a widespread 
occurring phenolic plant compound (flavonoid) with unpalatable astringent and protein precipitating 
properties [73].  
4.3. Lactoferrin 
Lactoferrin is an iron-binding cationic glycoprotein of 80 kDa which is present in most exocrine 
secretions, including saliva [63]. Major sources of lactoferrin in saliva are the salivary glands, 
neutrophil granulocytes entering the oral cavity [63], and the mucosal epithelial cells [13]. Lactoferrin 
is also present in the gingival crevicular fluid, which is also a significant source of lactoferrin present 
in the saliva [13]. Lactoferrin is active against bacteria, fungi, parasites and viruses [13,63]. Lactoferrin 
has a positive net charge and this cationic property seems to be an important factor which may lead to 
the binding and destruction of microbial cell membranes [63] as detailed above. Proteolytic cleavage 
generates smaller cationic peptide derivatives of 25 amino acids (or fewer) which exerts strong   
(iron-binding independent) bacteriolytic properties [74,75], very likely via electrostatic force-derived 
membrane adhesion and accumulation, followed by membrane destruction, as is usual in the case of 
cationic peptides (see above). Smaller derivatives seem to display pronounced antifungal activity as 
well [74]. Besides its cationic peptide activity, lactoferrin is a known scavenger of Fe
3+ ions [13].  
It binds and sequestrates iron, depriving microorganisms (i.e., bacteria, fungi and parasites) of the iron 
that is essential for their growth [63]. Lactoferrin also binds bacterial fimbrial adhesins, and therefore 
inhibit epithelial adhesion of certain bacteria [26]. Antiviral activity of lactoferrin [76] is expected to 
be based on binding (and blocking) of certain host cell glycosaminoglycans used by viruses for 
adsorption [63]. Lactoferrin may also neutralize viruses by direct binding [63]. Immune modulatory 
and anti-cancer activity of lactoferrin also seems likely [63]. 
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4.4. Cathelicidins (LL-37) 
Cathelicidins are characterized by a conserved N-terminal domain that is proteolytically cleaved to 
generate the active peptide [13,63,66]. The human cathelicidin is an 18 kDa cationic protein referred to 
as hCAP-18 [63,77]. Its most important active derivative is a 16 kDa peptide referred to as   
LL-37 [13,63]. LL-37 is an α-helix type cationic antimicrobial peptide, which may be further cleaved, 
resulting in smaller derivatives (RK-31, KS-30) of even higher antimicrobial activity [63,77]. Salivary 
LL-37 is likely to originate primarily from neutrophil leukocytes [13]. LL-37 is also present in the 
gingival crevicular fluid [13]. Since LL-37 (and its derivatives) are cationic peptides, their antibacterial 
effect is based on their aggregation onto microbial membranes and destruction via formation of ion 
channels, transmembrane pores, membrane leakages or membrane rupture [65]. LL-37 also binds and 
neutralizes bacterial lipopolysaccharides (LPS) [13]. Further, LL-37 and its derivatives are likely to 
play a role in the re-epithelialization of wounds and ulcers [78] in the oral cavity. LL-37 and its 
derivatives are also expected to exert immune activator and immune modulator properties [63]. 
4.5. Secretory Leukocyte Proteinase Inhibitor 
Secretory leukocyte protease inhibitor (SLPI) is an 117 kDa (107 amino acids) serine protease 
inhibitor, that controls excessive proteolysis caused by proteases (i.e., elastase, cathepsin G) of 
neutrophil granulocytes [13,63,79]. Therefore, SLPI is also referred to as antileukoprotease (ALP). 
Secretory leukocyte protease inhibitor (SLPI) present in saliva is produced by keratinocytes of the oral 
mucosa [13,63,80] as well as by neutrophil granulocytes entering the oral cavity [63]. SLPI is a   
non-glycosylated, basic, single-chain, cysteine rich cationic polypeptide [63]. Because of its cationic 
character, it is likely to act as a cationic peptide, aggregating onto microbial membranes and 
destruction of via the formation of ion channels, transmembrane pores, membrane leakages or 
membrane rupture. SLPI exerts antimicrobial activity against both bacteria (P. aeruginosa, S. aureus) 
and fungi (C. albicans) [13,81], and also exerts antiviral properties [80]. 
4.6. Adrenomedullin 
Adrenomedullin is a pluripotent hormone-like cationic peptide of 52 amino acids. It is present in the 
gingival crevicular fluid, glandular saliva and whole saliva [13,82]. It is also very likely that oral 
epithelial cells excrete adrenomedullin into the saliva [13,82,83]. Because of its cationic peptide 
character, adrenomedullin is able to kill bacteria [84,85] via aggregation onto bacterial membranes and 
destruction via the formation of ion channels, transmembrane pores, membrane leakages or rupture.  
It is also able to prevent bacterial growth (S. aureus) via generation of abnormal septum formation 
during cell division [85]. Adrenomedullin also dose dependently inhibits growth of several other 
bacteria via an unknown mechanism [82]. Proteolytic cleavage of adrenomedullin may lead to 
derivatives of even higher antimicrobial activity [85]. 
  Int. J. Mol. Sci. 2012, 13  4307 
 
 
5. Further Innate Defense Proteins of Saliva  
5.1. Lysozyme  
Lysozyme is a small (145 kDa) protein present in body fluids, including saliva. Salivary lysozyme 
is produced by the salivary glands (highest level was found in the sublingual saliva [86]) and also by 
neutrophil granulocytes entering the mouth [63]. It is also present in the gingival crevicular fluid [13]. 
Lysozyme exerts muramidaze activity via hydrolysis of the β-1,4-glycosidic bonds between   
N-acetylmuramic acid and N-acetyl-D-glucosamine of bacterial cell wall peptidoglycan. Lysozyme 
mainly kills gram-positive bacteria that damages surface-exposed peptidoglycan. The reduced 
susceptibility of most gram-negative species may be because of the outer membrane of these bacteria 
that shields the peptidoglycan layer from the environment [63]. Digestion of peptidoglycan structures 
via salivary lysozyme may also assist antimicrobial cationic peptides of saliva to get across 
peptidoglycan layers of bacterial membranes. It may also be hypothesized that cationic peptides may 
produce membrane leakage of the outer membrane of gram negative bacteria to assist lysozyme to 
reach the peptidoglycan layer of these bacterial membranes. Importantly, the killing of bacteria by 
lysozyme is, in many cases, largely independent of its enzymatic activity [87,88]. In these cases, the 
membrane permeabilizing property of lysozyme is likely to play a role [88]. This non-enzymatic 
antimicrobial property of lysozyme seems to be active against both gram-positive and gram-negative 
bacteria [88] as well as fungi [88,89]. Besides the above, lysozyme also exerts antiviral   
properties [90] and may also induce lysis of tumor cells [91]. Lysozyme also binds bacterial 
lipopolysaccharide (LPS) [92], a bacterial surface structure and bacterial toxin, frequently responsible 
for tissue destructive inflammatory reactions. It is also expected that lysozyme can influence human 
granulocyte and lymphocyte function, and may inactivate viruses [93]. 
5.2. BPI, BPI-like and PLUNC Proteins 
These proteins belong to the same lipid-binding protein family and show more or less similar 
molecular structures. Bactericidal/permeability increasing protein (BPI) is a 55 kDa cationic protein. 
Primary sources of salivary BPI are neutrophil granulocytes [63] and the epithelial cells of the oral 
mucosa [63]. BPI exerts bactericidal, endotoxin neutralizing and opsonic properties. BPI shows high 
affinity to the lipid-A moiety of bacterial lipopolysaccharide (LPS) structures. The antibacterial and 
endotoxin-neutralizing activity of BPI belongs to its LPS-binding N-terminal domain, whereas the 
opsonic property belongs to its C-terminal domain [63]. The most important representative of BPI-like 
proteins (bactericidal/permeability, increasing protein-like proteins) in the saliva is the parotid 
secretory protein (PSP) [13]. PSP is secreted by the salivary glands and also by the keratinocytes of the 
oral mucosa [13,94,95]. This protein is likely to be bacteriostatic, bind bacterial LPS and promote 
agglutination of bacteria [13]. Salivary PLUNC proteins (proteins of palate lung and nasal epithelial 
clone family) are primarily produced by the major and minor salivary glands [63,96]. There are eight 
functional PLUNC proteins in humans, which can be divided into two subgroups, such as short type  
S-PLUNC proteins (SPLUNC-1, SPLUNC-2, SPLUNC-3) and long type L-PLUNC proteins 
(LPLUNC-1, LPLUNC-2, LPLUNC-3, LPLUNC-4, LPLUNC-6) [63]. Short type PLUNC proteins 
consist of only one domain corresponding to the LPS-binding N-terminal domain of BPI, whereas long Int. J. Mol. Sci. 2012, 13  4308 
 
 
type PLUNC proteins consist of two domains similar to the whole BPI molecule [63]. PLUNC proteins 
appear to be able to bind bacterial LPS similar to BPI [63]; however, PLUNC proteins are not likely to 
exert direct killing activity (they are likely to be bacteriostatic, similarly to PSP) [63]. PLUNC proteins 
are also likely to promote agglutination of bacteria and to modulate cytokine production [63]. 
5.3. α-Amylase 
Salivary amylase is a highly abundant protein in saliva. The highest concentration of amylase was 
found in the saliva of the parotid gland and palatine minor salivary glands [86,97]. Eight isoforms 
contain asparagine-linked sugar chains and are around 61–63 kDa [6,98,99], whereas other eight 
isoforms do not have such chains are around 56–59 kDa [6,98,99]. The most widely-known function of 
amylase is endoglicosidase activity. Splitting the α-1,4-glicosidic bindings of several glycans, such as 
starch (amylopectin), amylase produces oligosaccharides (dextrin) disaccharides (maltose, isomaltose) 
and monosaccharide glucose. Beside its enzymatic activity, amylase also takes part in acquired pellicle 
formation on tooth surfaces [98,100,101]. Amylase also binds bacteria [92,98,101], including certain 
bacterial pili [102] which are important factors of bacterial adhesion. Thus, amylase promotes bacterial 
adhesion to the hydroxyapatite surfaces of teeth [100,101], which can lead to both advantageous 
surface immune exclusion on the one hand and disadvantageous adhesion of cariogenic or 
periodontopathogenic bacteria onto tooth surfaces on the other hand. In contrast, the binding of 
bacteria may also lead to the prevention of bacterial surface adhesion via saturation of bacterial 
adherence factors of “floating” planktonic bacteria (i.e., like bacterial pili [102]) and consequent 
bacterial clearance towards the stomach [98] resulted in acidic digestion. It was also demonstrated that 
amylase performs a direct inhibitory effect on the growth of certain bacteria [30,98,103]. Amylase also 
binds bacterial lipopolysaccharide (LPS) [92], a bacterial surface structure and bacterial toxin, 
responsible, in many cases, for tissue destructive inflammatory reactions. Amylase may also exert 
virus inhibitory properties [104]. 
5.4. Cystatins 
The human cystatin gene family contains 14 genes (including two pseudogens) from which seven 
cystatins are present in saliva [13], namely cystatin-A, cystatin-B, cystatin-C, cystatin-D, cystatin-S, 
cystatin-SA and cystatin-SN [13]. The highest concentration of cystatins was found in the 
submandibular saliva [86], but (at a much lower concentration) they are also present in the parotid 
saliva [105]. Cystatins are also present in the gingival crevicular fluid [106]. Cystatins are cysteine 
protease inhibitors that block the action of endogenous [13,105], bacterial [13] and parasitic protozoan 
proteases [105]. Cystatin-C and cystatin-S were shown to inhibit bacterial growth (P. gingivalis) [107]. 
Cystatin-SN and cystatin-S are present in the human-acquired enamel pellicle [9] and also bind 
bacteria [92] as well as bacterial lipopolysaccharides (LPS) [92], which are bacterial surface structures 
and toxins frequently responsible for tissue destructive inflammatory reactions. Cystatins also exert 
direct immunomodulatory properties [105]. They are also likely to exert certain antiviral effect [105]. 
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5.5. Proline-Rich Proteins (PRPs) 
Proline-rich proteins form a major fraction of salivary proteins (ca. 20–30 % of total), the molecular 
weight of acidic and basic PRPs is usually between 10–40 kDa, whereas large glycosylated PRPs have 
a molecular weight of 60–70 kDa [108]. Proline-rich proteins (PRPs) are highly phosphorylated 
proteins [73]. The major source of salivary proline-rich proteins (PRPs) are the salivary glands [2]; the 
highest concentration of PRPs was found in the parotid saliva [86]. PRPs are encoded by seven genes, 
and many of them are subsequently cleaved by proprotein convertases before secretion, consequently a 
large number (more than 20) PRPs exist. Acidic PRPs contain a longer and highly acidic   
N-terminal region, and a somewhat different repeat sequence, compared with basic PRPs [73]. Acidic 
PRPs exert calcium hydroxide-binding properties, and therefore participate in the formation of 
acquired pellicle (a thin, 0.5–1 μm protein layer) on the surface of teeth [2,9]. Basic PRPs are also 
present in the human-acquired enamel pellicle [9]. Acidic PRPs bind bacteria, basic PRPs bind fungi 
(e.g., Candida albicans) and viruses, whereas glycosylated PRPs bind bacteria and viruses that indicate 
the role of PRPs in the clearance towards the stomach and/or surface exclusion of these   
microorganisms [2,30,109]. PRPs are also potent precipitators of tannins, similarly to histatins [73].  
5.6. Salivary Mucins 
There are two major subtypes of mucins, namely the membrane associated and the secreted 
type [110]. In the oral cavity, membrane associated type mucins (i.e., MUC-1) are primarily secreted 
by the oral mucosal epithelial cells [110]. These proteins mainly remain on the cell surface (in the 
mucus layer of mucosa) after secretion [110], and are primarily involved in the protection of epithelial 
surfaces [110]. There is also a much higher amount of secreted type mucins present in the oral cavity, 
from which salivary mucins MUC5b and MUC7 (older terms: MG1 and MG2) are the most important 
subtypes [2,86,111,112]. Salivary mucins are rather large and highly glycosylated proteins [112]. 
MUC5b has a molecular weight of higher than 1000 kDa and is composed of disulphide linked 
subunits [112]; whereas MUC7 is a monomer of approximately 180–200 kDa [112]. Salivary mucins 
are produced primarily by the submandibular gland and by the labial and palatinal minor salivary 
glands [86,111]. The highest concentration of salivary mucins was found in the saliva of sublingual 
glands (Mg1, MG2) and palatine minor salivary glands (high molecular weight mucins) [86]. Besides 
taking part in acquired pellicle formation on tooth surfaces (especially MUC5b type mucins [2,111]), 
salivary mucins cover all oral surfaces with an at least 10–22 μm (up to 40–60 μm [113]) thick  
layer [2,113]. In addition, MUC5b-type mucins form a hydrophilic viscoelastic gel (in low 
concentration) that causes a high viscosity matrix of saliva [2,113]. Salivary mucins, especially MUC7, 
have a high affinity to microorganisms, and entrap and agglutinate bacteria, fungi and viral   
particles [2,13]. MUC5b was also shown to exert antiviral properties [17]. Bactericidal and antifungal 
properties of a cationic peptide (MUC7 12-mer) derived from the N-terminal region of MUC7 was  
also reported [114].  




There are two principal components of the peroxidase system of saliva, namely lactoperoxidase and 
myeloperoxidase [115]. Lactoperoxidase is produced by the salivary glands, whereas myeloperoxidase 
is produced by neutrophil granulocytes entering the oral cavity [13]. Myeloperoxidase is also present 
in the gingival crevicular fluid [13]. Both lactoperoxidase (salivary peroxidase) and myeloperoxidase 
catalyze the oxidation of thiocyanate ions (SCN-) by hydrogen peroxide, leading to the production of a 
much more bactericidal [116] and fungicidal [116] agent, namely hypothiocyanite (OSCN-) [117]. 
Importantly, this function of salivary peroxidase seems to be facilitated by Duox-2, a homologue of the 
catalytic core (gp91) of NADPH oxidases [118,119]. Duox-1 is localized in the luminal plasma 
membrane of epithelial cells of major (terminal) collecting ducts of salivary glands [118, 119], and 
provides hydrogen peroxide (the most labile component of the system) for salivary peroxidase just 
prior to delivery into the oral cavity [118,119]. 
5.8. Statherin 
Statherin is a 5.4 kDa (43 residues) tyrosine- glutamine- and proline -rich phosphoprotein.   
It inhibits precipitation of calcium phosphate salts from saliva, which is supersaturated with respect to 
these salts [120,121]. Furthermore, statherin not only inhibits the crystal growth of calcium phosphate 
salts, but also inhibits spontaneous (unseeded) precipitation from solutions supersaturated with respect 
to calcium phosphate salts (such as saliva). Further, statherin binds hydroxyapatite [9,30,120,121], 
indicating a possible role in acquired pellicle and dental plaque formation. On the other hand, statherin 
competitively inhibits the absorption of high molecular weight glycoproteins (HMWGPs) to tooth 
surfaces, and therefore may inhibit adhesion of HMWGP-binding cariogenic bacteria, including 
Streptococcus mutans [70]. Interestingly, statherin is likely to be enriched in the air interface of the 
saliva film present in the mouth [122]; which also may be an indication that the binding of bacteria by 
statherin more likely leads to aggregation and clearance towards the stomach than to surface adhesion. 
Besides its antibacterial properties, statherin also induces transition of hyphae (the most invasive form 
of the fungus) to yeast in Candida albicans [16]; indicating that statherin is likely to contribute to oral 
defense against fungi [16].  
5.9. Salivary Agglutinin (SAG, gp-340) 
Salivary agglutinin (SAG) is a scavenger-receptor cysteine-rich glycoprotein [123]. It is also 
referred to as lung glycoprotein-340 (gp-340) and also as protein deleted in malignant brain tumors 
(DMBT-1) [123]. In the saliva, SAG acts as a pattern recognition scavenger receptor, and as such, it 
binds a broad range of oral pathogens, including bacteria and viruses [123,124,125]. Similarly, SAG 
also binds salivary proteins, including IgA and mucin MUC5b [123]. Based on premised properties, 
SAG efficiently aggregates bacteria and viruses, and significantly increases their clearance from the 
mouth towards the stomach, leading to their acidic digestion [126]. Salivary agglutinin (SAG) is also 
present in the acquired pellicle on the tooth surfaces and in the mucous layer on the mucosal cell 
surfaces [126]. Thus, it may promote bacterial/viral adhesion onto oral surfaces [126], which may lead 
either to pathogenic invasion and/or the surface exclusion of pathogens. However, the majority of SAG Int. J. Mol. Sci. 2012, 13  4311 
 
 
is found soluble in saliva; therefore, surface related effects are of less importance in the oral   
cavity [126]. Besides its efficient antibacterial and antiviral properties [17,124,125], salivary agglutinin 
also shows certain immune activator/modulator activities [123].  
5.10. Other Defense Proteins of Innate Immunity 
There are likely to be numerous other defense proteins present in saliva from which at least 
calprotectin and three bacteria binding proteins should be mentioned. Calprotectin is a dimer of 
calgranulin-A and calgranulin-B with metal ion-binding properties [13]. Calprotectin inhibits microbial 
growth by acting as a divalent cation (i.e., Mn
2+, Zn
2+) scavenger [127]. The major sources of salivary 
calprotectin are oral epithelial cells and neutrophil granulocytes [13] entering the oral cavity. 
Calprotectin is also present in the gingival crevicular fluid [128]. There are three bacteria and   
LPS-binding proteins, namely prolactin inducible protein (PIP), lipocalin (LCN) and submandibular 
gland androgen-regulated protein (SMR) which should also be mentioned. These proteins bind bacteria 
and bacterial lipopolysaccharide (LPS), which is a bacterial surface structure and bacterial toxin, 
frequently responsible for tissue destructive inflammatory reactions [92].  
6. Conclusions 
Whole saliva is a major determinant of the environment on all the oral surfaces. On tooth surfaces, 
saliva plays an important role in acquired pellicle formation, which in turn plays a major role in crystal 
growth homeostasis and physico-chemical defense of the teeth [1,2] as well as in bacterial adhesion 
(and colonization) to tooth surfaces which may lead to caries formation and periodontal   
inflammation [1,2]. Acquired pellicle, however, may also be considered as an important tool for 
advantageous surface exclusion of transient pathogen microbes entering the mouth. Saliva also plays 
an important role in physico-chemical as well as immune defense of oral mucosal surfaces (via both 
direct antimicrobial action and agglutination or surface exclusion of microbes). Saliva also plays an 
important role in the fine regulation (activation/modulation) of oral mucosal immune reactions, as well 
as in healing of several mucosal lesions, wounds and ulcers [1,2]. There are numerous defense proteins 
present in the saliva. Some of these defense proteins, such as salivary immunoglobulins and salivary 
chaperokine HSP70/HSPAs are involved in both innate and acquired immune activation [2,3,4], 
whereas cationic peptides and other salivary defense proteins are primarily responsible for innate 
immunity [1,2]. Notwithstanding that, many of these molecules are present in a rather low 
concentration in whole saliva [13]; local concentrations of these proteins near the mucosal surfaces, 
periodontal sulcus and oral wounds and ulcers (transudate) may be much greater. Moreover, in many 
cases their effect is reinforced by immune and/or inflammatory reactions of the oral mucosa [3,4]. 
Their local concentration may also be high on mucosal and tooth surfaces [6,7,8,9], in the salivary  
micelles [11,12] and near the immune cells entering the oral cavity. Their effects are also additive 
and/or synergistic, resulting in an efficient molecular defense network of the oral cavity [1,2,5]. In this 
latter case, a network type “multi-hit” approach may be expected, during which different kinds of 
salivary defense proteins affect a targeted microbe at the same time. Most salivary defense proteins 
(and peptides) are multifunctional [1,2,5] and their actions overlap in several cases [1,2], which serves 
as a good basis for this “multi hit” network type defense action. Int. J. Mol. Sci. 2012, 13  4312 
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